DIAG-723 / Diagonal Therapeutics - LARVOL DELTA

Diagonal's First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) (The Manila Times) - "Diagonal Therapeutics...announced that both the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to DIAG723, a novel, bispecific antibody, for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the European Medicines Agency (EMA) provided a positive opinion for ODD, confirming that DIAG723 meets the criteria for designation as an orphan drug in the European Union."

Orphan drug • Genetic Disorders